TY - JOUR
T1 - Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
AU - Pouillon, Lieven
AU - Van Stappen, Johan
AU - Bossuyt, Peter
AU - Danese, Silvio
AU - Peyrin-Biroulet, Laurent
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Randomized controlled trials with direct comparisons between the different available biological agents in ulcerative colitis are lacking. The comparative efficacy, safety and tolerability, patient profile, patient preference and costs should be taken into account when choosing an appropriate first-line biological. Tumor necrosis factor antagonists have a systemic mode of action, while vedolizumab is mainly gut-selective, and this influences the clinical profile of both treatment options. Tofacitinib will further expand the therapeutic armamentarium in ulcerative colitis. Results of ongoing head-to-head trials between biological agents are likely to change clinical practice in the near future. Biomarkers that predict response to different treatment options in an individual patient are warranted.
AB - Randomized controlled trials with direct comparisons between the different available biological agents in ulcerative colitis are lacking. The comparative efficacy, safety and tolerability, patient profile, patient preference and costs should be taken into account when choosing an appropriate first-line biological. Tumor necrosis factor antagonists have a systemic mode of action, while vedolizumab is mainly gut-selective, and this influences the clinical profile of both treatment options. Tofacitinib will further expand the therapeutic armamentarium in ulcerative colitis. Results of ongoing head-to-head trials between biological agents are likely to change clinical practice in the near future. Biomarkers that predict response to different treatment options in an individual patient are warranted.
KW - Adalimumab
KW - Anti-tumor necrosis factor
KW - Golimumab
KW - Inflammatory bowel disease
KW - Infliximab
KW - Ulcerative colitis
KW - Vedolizumab
UR - http://www.scopus.com/inward/record.url?scp=85047059595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047059595&partnerID=8YFLogxK
U2 - 10.1016/j.bpg.2018.05.006
DO - 10.1016/j.bpg.2018.05.006
M3 - Review article
C2 - 30060934
AN - SCOPUS:85047059595
VL - 32-33
SP - 17
EP - 25
JO - Bailliere's Best Practice and Research in Clinical Gastroenterology
JF - Bailliere's Best Practice and Research in Clinical Gastroenterology
SN - 1521-6918
ER -